Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models
Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.